

IMPACT FACTOR 3.4

Indexed in: PubMed



an Open Access Journal by MDPI

Precision Medicine for Acute Respiratory Distress Syndrome (ARDS)

Guest Editor:

Dr. Jan Máca

1. Department of Anesthesiology and Intensive Care Medicine, University Hospital of Ostrava, Ostrava-Poruba, Czech Republic 2. Institute of Physiology and Pathophysiology, Department of Intensive Care Medicine and Forensic Studies, Faculty Of Medicine, University Of Ostrava, Ostrava, Czech Republic 3. Department of Intensive Medicine, Emergency Medicine and Forensic Studies, Faculty Of Medicine, University of Ostrava, Ostrava, Czech Republic

Deadline for manuscript submissions:

closed (10 July 2023)

Message from the Guest Editor

Acute respiratory distress syndrome (ARDS) is the most severe form of respiratory failure, significantly affecting the morbidity and mortality of critical care patients. ARDS is caused by various lung-injuring factors, leading to seemingly similar clinical manifestations requiring uniform management. However, the disease course and outcomes usually significantly differ in terms of the type of injury, intensity, and time of action of the factor. Differences can also be found between patients suffering from the same Phenotypic divisions of ARDS related extrapulmonary and pulmonary causes can be considered some of the most clinically relevant. ARDS is based on two principal pathways leading to lung injury and, among other issues, encompasses different responses to therapeutic interventions. Phenotypes of ARDS are nowadays one of the leading ARDS-related topics.

In this Special Issue, we welcome authors to submit papers concerning various injury-specific types of ARDS, focusing on pathophysiologic and phenotypic differences and the relationship with possible future changes in diagnostic and treatment approaches.







IMPACT FACTOR 3.4





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

 Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
Division of Hematologic Malignancies and Cellular Therapy, Duke University,

Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous*))

Contact Us